Organogenesis Holdings Inc.
ORGO
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $220.0M
$1.71
▲ +4.27%
P/E
-2.06
Mkt Cap
$220.0M
52-Wk Range
$1.54–$7.08
52-Week Range
$1.54 - $7.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 64.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bioengineered tissue technology preserving viable cells and growth factors
- Diversified product portfolio addressing multiple clinical applications and market segments
- Established manufacturing expertise and FDA-approved products with proven clinical efficacy
- Direct sales force and distribution network providing strong market access and customer relationships
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Expanding advanced wound care market driven by aging population and chronic disease prevalence
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Falling
-28.1% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ORGO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.71 vs -$0.35 consensus (-102.9% surprise). Revenue of $43.8M vs $54.3M expected (-19.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-102.9%
Revenue trend · last 8Q
—
+27%
-21%
-23%
+31%
+78%
-57%
-57%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$115.2M
$126.7M
$86.7M
$100.8M
$150.9M
$225.6M
$37.2M
$43.8M
Margins · last 8Q
Gross
0.0%
Operating
-116.5%
Profit
-227.0%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Truist · $3.00 · May 28, 2026
vs Industry
How ORGO stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related